Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pfizer Inc (PFE)

Pfizer Inc (PFE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

As the FDA Approves a Wegovy Pill, Should You Buy, Sell, or Hold Novo Nordisk Stock?

Novo Nordisk A/S ADR (NVO), a trailblazer in the weight-loss revolution, has endured a bruising 2025. The Danish pharma giant has been hit by trimmed growth forecasts, pricing pressure, rising competition from Eli Lilly (LLY), mass layoffs, dramatic leadership changes, and even a high-profile public bidding war with U.S. rival Pfizer (PFE). Although Novo’s blockbuster Ozempic enjoyed a four-year head start over Lilly’s Mounjaro, Lilly has now pulled ahead in U.S. prescriptions.

Novo’s struggles to keep up with demand also allowed compounding pharmacies to step in, chipping away at its market share and making 2025 one...

Fundamentals

See More
  • Market Capitalization, $K 142,654,416
  • Shares Outstanding, K 5,685,708
  • Annual Sales, $ 63,627 M
  • Annual Income, $ 8,031 M
  • EBIT $ 18,723 M
  • EBITDA $ 25,736 M
  • 60-Month Beta 0.46
  • Price/Sales 2.24
  • Price/Cash Flow 5.74
  • Price/Book 1.53

Options Overview Details

View History
  • Implied Volatility 23.36% (+0.61%)
  • Historical Volatility 24.03%
  • IV Percentile 26%
  • IV Rank 15.05%
  • IV High 52.17% on 04/10/25
  • IV Low 18.25% on 08/18/25
  • Expected Move (DTE 4) 0.31 (1.25%)
  • Put/Call Vol Ratio 0.88
  • Today's Volume 115,615
  • Volume Avg (30-Day) 134,014
  • Put/Call OI Ratio 0.78
  • Today's Open Interest 2,978,343
  • Open Int (30-Day) 3,338,545
  • Expected Range 24.78 to 25.40

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 24 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.58
  • Number of Estimates 4
  • High Estimate 0.68
  • Low Estimate 0.48
  • Prior Year 0.63
  • Growth Rate Est. (year over year) -7.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
24.83 +1.05%
on 12/23/25
26.65 -5.85%
on 12/15/25
-0.62 (-2.41%)
since 11/26/25
3-Month
23.64 +6.13%
on 09/29/25
27.69 -9.39%
on 10/03/25
+1.33 (+5.60%)
since 09/26/25
52-Week
20.92 +19.96%
on 04/09/25
27.69 -9.39%
on 10/03/25
-1.47 (-5.53%)
since 12/26/24

Most Recent Stories

More News
As the FDA Approves a Wegovy Pill, Should You Buy, Sell, or Hold Novo Nordisk Stock?

As Novo Nordisk’s FDA-approved Wegovy pill sets up a high-stakes comeback, should NVO be back on investors’ radar now?

NVO : 52.40 (-0.30%)
$SPX : 6,929.94 (-0.03%)
LLY : 1,077.75 (+0.07%)
PFE : 25.09 (+0.24%)
MarketBeat Week in Review – 12/15 - 12/19

Money continues to move into the market, raising hopes for a Santa Claus rally; however, the macro story remains mixed, which could bring more volatility

NFLX : 94.47 (+0.89%)
APP : 714.23 (-1.82%)
GOOGL : 313.51 (-0.18%)
CSCO : 78.16 (+0.18%)
SMCI : 30.64 (+0.29%)
MU : 284.79 (-0.66%)
UPWK : 20.85 (-0.57%)
MDB : 435.85 (+0.08%)
PFE : 25.09 (+0.24%)
TSM : 302.84 (+1.35%)
TSLA : 475.19 (-2.10%)
XLF : 55.62 (-0.20%)
Trump announces lower drug price deals with 9 pharmaceutical companies

U.S. President Donald Trump announced Friday that nine drugmakers have agreed to lower the cost of their prescription drugs in the U.S. Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead...

AZN.LN : 13,736.000 (+0.45%)
GILD : 124.70 (-0.77%)
AMGN : 332.93 (-0.31%)
PFE : 25.09 (+0.24%)
Pfizer Invites Public to View and Listen to Webcast of February 3 Conference Call with Analysts

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EST on Tuesday, February 3, 2026. The purpose...

PFE : 25.09 (+0.24%)
PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

TOKYO and NEW YORK , Dec. 17, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) today announced positive topline results...

PFE : 25.09 (+0.24%)
S&P Futures Gain as Investors Weigh U.S. Jobs Data, Fed Speak and Micron Earnings in Focus

December S&P 500 E-Mini futures (ESZ25) are trending up +0.27% this morning as investors continue to digest the latest U.S. jobs data, while also awaiting remarks from Federal Reserve officials and an...

NFLX : 94.47 (+0.89%)
HUM : 258.83 (-0.16%)
BKR : 45.25 (-0.11%)
MU : 284.79 (-0.66%)
ABNB : 136.82 (+0.03%)
PFE : 25.09 (+0.24%)
GIS : 47.05 (+0.11%)
OXY : 39.85 (-0.38%)
APA : 24.18 (-0.74%)
CMCSA : 29.66 (-0.40%)
PSX : 127.75 (-0.51%)
FANG : 146.31 (-0.41%)
Wall Street slips as oil prices keep dropping

The U.S. stock market drifted through a mixed day of trading after reports on the economy did little to clear uncertainty about where interest rates may be heading

NVDA : 190.53 (+1.02%)
MPC : 163.69 (-1.23%)
AVGO : 352.13 (+0.55%)
$SPX : 6,929.94 (-0.03%)
F : 13.31 (-0.37%)
K : 83.44 (-0.01%)
GS : 907.04 (-0.41%)
$IUXX : 25,644.39 (-0.05%)
PFE : 25.09 (+0.24%)
CRWV : 76.42 (-3.11%)
HAL : 27.96 (-0.25%)
IRBT : 0.4664 (-30.05%)
Stocks Settle Mixed on Soft US Economic News

The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed down by -0.24%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down by -0.62%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up by +0.26%. ...

MPC : 163.69 (-1.23%)
GOOGL : 313.51 (-0.18%)
AAPL : 273.40 (-0.15%)
GTLB : 37.84 (+0.96%)
CVX : 150.02 (-0.32%)
$IUXX : 25,644.39 (-0.05%)
ITW : 252.46 (+0.20%)
PFE : 25.09 (+0.24%)
ZNH26 : 112-230 (+0.12%)
MSFT : 487.71 (-0.06%)
OXY : 39.85 (-0.38%)
TSLA : 475.19 (-2.10%)
Stocks Slide on Sluggish US Economic News

The S&P 500 Index ($SPX ) (SPY ) today is down by -0.32%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down by -0.293%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.14%. December E-mini...

MSTR : 158.81 (+0.06%)
MPC : 163.69 (-1.23%)
GTLB : 37.84 (+0.96%)
F : 13.31 (-0.37%)
GLXY : 23.40 (-4.22%)
$IUXX : 25,644.39 (-0.05%)
ITW : 252.46 (+0.20%)
COIN : 236.90 (-1.18%)
PFE : 25.09 (+0.24%)
ZNH26 : 112-230 (+0.12%)
OXY : 39.85 (-0.38%)
ESH26 : 6,965.25 (-0.20%)
Stocks Slightly Lower on US Economic Concerns

The S&P 500 Index ($SPX ) (SPY ) today is down by -0.14%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down by -0.13%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up by +0.03%. December E-mini S&P...

GTLB : 37.84 (+0.96%)
F : 13.31 (-0.37%)
$IUXX : 25,644.39 (-0.05%)
ITW : 252.46 (+0.20%)
PFE : 25.09 (+0.24%)
ZNH26 : 112-230 (+0.12%)
OXY : 39.85 (-0.38%)
ESH26 : 6,965.25 (-0.20%)
FANG : 146.31 (-0.41%)
VLO : 164.01 (-0.28%)
$DOWI : 48,710.97 (-0.04%)
SPY : 690.31 (-0.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare...

See More

Key Turning Points

3rd Resistance Point 25.35
2nd Resistance Point 25.23
1st Resistance Point 25.16
Last Price 25.09
1st Support Level 24.97
2nd Support Level 24.85
3rd Support Level 24.78

See More

52-Week High 27.69
Fibonacci 61.8% 25.10
Last Price 25.09
Fibonacci 50% 24.30
Fibonacci 38.2% 23.50
52-Week Low 20.92

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar